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Incidence of Surgical Site Infection Following Mastectomy With and
Without Immediate Reconstruction Using Private
Insurer Claims Data
Margaret A. Olsen, PhD, MPH;1,2 Katelin B. Nickel, MPH;1 Ida K. Fox, MD;3 Julie A. Margenthaler, MD;4
Kelly E. Ball, BSN, MPH;1 Daniel Mines, MD, MSCE;5 Anna E. Wallace, MPH;5 Victoria J. Fraser, MD1

objective. The National Healthcare Safety Network classiﬁes breast operations as clean procedures with an expected 1%–2% surgical site
infection (SSI) incidence. We assessed differences in SSI incidence following mastectomy with and without immediate reconstruction in a large,
geographically diverse population.
design.

Retrospective cohort study

patients. Commercially insured women aged 18–64 years with ICD-9-CM procedure or CPT-4 codes for mastectomy from January 1, 2004
through December 31, 2011
methods. Incident SSIs within 180 days after surgery were identiﬁed by ICD-9-CM diagnosis codes. The incidences of SSI after mastectomy
with and without immediate reconstruction were compared using the χ2 test.
results. From 2004 to 2011, 18,696 mastectomy procedures among 18,085 women were identiﬁed, with immediate reconstruction in
10,836 procedures (58%). The incidence of SSI within 180 days following mastectomy with or without reconstruction was 8.1% (1,520 of
18,696). In total, 49% of SSIs were identiﬁed within 30 days post-mastectomy, 24.5% were identiﬁed 31–60 days post-mastectomy, 10.5% were
identiﬁed 61–90 days post-mastectomy, and 15.7% were identiﬁed 91–180 days post-mastectomy. The incidences of SSI were 5.0% (395 of
7,860) after mastectomy only, 10.3% (848 of 8,217) after mastectomy plus implant, 10.7% (207 of 1,942) after mastectomy plus ﬂap, and 10.3%
(70 of 677) after mastectomy plus ﬂap and implant (P < .001). The SSI risk was higher after bilateral compared with unilateral mastectomy with
immediate reconstruction (11.4% vs 9.4%, P = .001) than without (6.1% vs 4.7%, P = .021) immediate reconstruction.
conclusions. SSI incidence was twice that after mastectomy with immediate reconstruction than after mastectomy alone. Only 49% of SSIs
were coded within 30 days after operation. Our results suggest that stratiﬁcation by procedure type facilitates comparison of SSI rates after breast
operations between facilities.
Infect Control Hosp Epidemiol 2 01 5; 3 6( 8) :9 0 7– 9 14

Surgical site infection (SSI) is the most common healthcareassociated infection among hospitalized patients in the United
States.1 SSI incidence reported by the National Healthcare
Safety Network (NHSN) after breast operations from 2006 to
2008 was 2.3% for inpatient breast operations and 0.6% for
outpatient breast operations.2 The NHSN recommends
surveillance for SSIs for 30 days or 90 days after surgery if
an implant is involved, and the NHSN combines all breast surgical procedures into a single category (eg, breast-conserving
surgery (BCS), reduction mammoplasty, mastectomy, and
implant and ﬂap reconstruction).3
In contrast to the low incidence reported by the NHSN,
breast surgery SSI rates reported from individual institutions

vary widely. The variation in reported rates depends on the
type of breast operation, deﬁnitions used for infection,
surveillance methods to identify infections, and length of
postoperative follow-up.4 Using standardized surveillance for
1 year after surgery, we previously reported SSI rates for
speciﬁc breast operations at a single institution ranging from
1.1% after reduction mammoplasty, 4.4% after mastectomy,
6.2% after mastectomy with immediate ﬂap reconstruction, to
12.4%–16.5% after mastectomy with immediate implant.5,6
The goal of our study was to determine the incidence of SSI
in a large population of women with private health insurance
following mastectomy with and without immediate implant or
ﬂap reconstruction performed at many different facilities.
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m a t e r i a l s an d m e t h o d s
Data Source
We conducted a retrospective cohort study using data from 12
Anthem-afﬁliated plans in the HealthCore Integrated Research
Database (HIRDSM).7 Collected data included all fully adjudicated claims submitted from providers, facilities, and outpatient pharmacies linked to health-plan enrollment
information. Fully insured women enrolled in a fee-for-service
plan with medical coverage of hospital and physician services
were eligible for inclusion in the cohort. Due to unique risk
factors for infection, we excluded women coded for end-stage
renal disease, organ transplant, or HIV-positive status. Medical
claims were restricted to paid claims.
The database contained up to 5 diagnosis codes [International
Classiﬁcation of Diseases, 9th Revision, Clinical Modiﬁcation
(ICD-9-CM)] per claim from 2004 to 2008 and up to 12
diagnosis codes per claim from 2009 to 2011. Inpatient
hospitals included up to 5 ICD-9-CM procedure codes per
claim (8 in 2009–2011), whereas provider and ambulatory
facility claims used CPT-4 (Current Procedural Terminology,
4th edition) codes.
Patient Population
We identiﬁed mastectomy operations with at least 1 day followup after operation among women aged 18–64 years from
January 1, 2004 to December 31, 2011 using ICD-9-CM and/or
CPT-4 procedure codes from inpatient and outpatient facility
and provider claims (Online Appendix 1). Because of coding
inaccuracy and the limited clinical detail in claims data, we
implemented steps to increase the likelihood that the procedures we included were truly mastectomies, as described below.
We allowed a maximum of 2 mastectomies per woman during
the study period. We excluded claims that contained CPT-4,
HCPCS, or UB-04 revenue codes truncated to 4 digits or that
populated ﬁelds reserved for ICD-9-CM procedure codes, as
well as claims in which a mastectomy procedure code was
present only on 1 line on a single claim with no other claims on
the same date, as described previously.8
In 1,300 (6.7%) operations, CPT-4 or ICD-9-CM procedures
codes for BCS were present during the same hospital admission or
within 3 days of mastectomy. Because concurrent BCS and
mastectomy is unlikely and because the incidence of SSI after BCS
is lower than after mastectomy, we created an algorithm to
determine the most likely procedure. We included any of the
following information as evidence that mastectomy was performed: procedure code for reconstruction (Online Appendix 1),
CPT-4 pathology code 88309 (modiﬁed radical mastectomy),
prophylactic removal of the breast (V50.41), mastectomy
coded by both facility and surgeon, BCS and mastectomy on
opposite breasts per CPT-4 modiﬁer codes, BCS coded only by
an assistant surgeon, or diagnosis of acquired absence of the
breast in the year following surgery (V45.71). We excluded
procedures more consistent with BCS, including surgeon

coding only for BCS (mastectomy-only coded by assistant
surgeon or facility), and other diagnoses and procedures consistent with BCS but not mastectomy (Online Appendix 2).9
Establishing the Surgery Date
Different mastectomy dates within 7 days were counted as a single
surgery date because of potential date inaccuracy, particularly on
provider claims.10 When 2 or more dates within 7 days were
coded for mastectomy, we incorporated supplemental evidence
from unique provider claims for reconstruction, anesthesia, and
pathology to determine the most likely surgery date. We excluded
facility- and provider-only mastectomy claims that lacked
additional evidence for operation, including anesthesia, pathology,
or a surgery revenue code (Online Appendix 1).9
Classiﬁcation of Procedures
We classiﬁed the mastectomy as unilateral or bilateral based
on ICD-9-CM procedure and CPT-4 codes, billed units, and
CPT-4 modiﬁer codes (Online Appendix 1). When discrepancies
occurred between the provider and facility, we considered the
procedure to be bilateral unless there was only a single billed unit
for pathology. We deﬁned immediate reconstruction based on
procedure codes for tissue expander/breast implant and/or ﬂap
reconstruction within 7 days of mastectomy (Online Appendix 1).
We prioritized the provider classiﬁcation of the ﬂap in the case
of discrepant facility and provider information. We did not use
facility CPT-4 codes to classify ﬂap reconstruction because ﬂap
procedures are not performed in ambulatory surgeries. Similarly, we did not classify ﬂap reconstruction if it was only coded
by a facility with length of stay <2 days using ambiguous
procedure codes (ICD-9-CM 85.7, 85.70, or 85.79), due to
likely misclassiﬁcation (eg, local tissue rearrangement for
wound closure coded as a ﬂap).
Indication for Mastectomy
We used ICD-9-CM diagnosis codes to identify carcinoma
in situ (CIS), locally invasive, regionally invasive, and
metastatic breast cancer, as described previously.9 We classiﬁed the indication for mastectomy at the time of the ﬁrst
operation ranked hierarchically: metastatic, regional, local
breast cancer, CIS, or benign/prophylactic mastectomy.
Mastectomy was considered prophylactic if an ICD-9-CM
diagnosis for prophylactic breast removal, family history
(V16.3), or genetic susceptibility to breast neoplasm (V84.01)
was coded within 7 days of surgery. Because the majority of
second or contralateral mastectomies are prophylactic,11,12 we
ranked prophylactic codes highest for subsequent operations.
If no prophylactic diagnoses were coded within 7 days of the
second operation, we used the cancer-stage hierarchy.
Identiﬁcation and Timing of Surgical Site Infection
SSIs ﬁrst coded from 2 to 180 days after surgery were identiﬁed
using ICD-9-CM diagnosis codes from inpatient and

ssi post mastectomy and reconstruction

outpatient facilities and provider claims (Online Appendix 3).
Coding of Staphylococcus aureus within 7 days of ≥1 of the
following was considered consistent with an SSI: procedure
code for incision/drainage, diagnosis of a noninfectious wound
complication, or cellulitis. In accordance with the NHSN
deﬁnition,3 a diagnosis code for cellulitis on the same claim as
a procedure code for incision/drainage or on the day of
implant removal without insertion was classiﬁed as an SSI. We
previously validated these diagnosis codes in breast surgery
patients within 180 days of surgery using microbiology and
clinical data based on the NHSN deﬁnition for SSI.13
We excluded claims with laboratory CPT-4 codes (88104–
88399) because these diagnosis codes may have indicated
diagnostic workup. Because ICD-9-CM diagnosis code 611.0
could indicate either breast infection or inﬂammatory breast
cancer, we did not use it as evidence for SSI if it was also coded
in the month before mastectomy. Because our goal was to
identify infections attributable to surgery, we excluded cellulitis codes after the start of radiotherapy.
SSI onset was deﬁned according to the timing and location
of diagnosis. For SSIs newly coded by an inpatient facility
during the original operative admission, we assigned the date
of SSI to the discharge date if the difference between the discharge and admission date was ≥2 days. For SSIs diagnosed
during a subsequent inpatient admission, SSI onset was
assumed to be the hospital readmission date. For SSIs diagnosed initially by a provider or in an outpatient setting, the
onset date was deﬁned as the ﬁrst service date.
The SSI observation period was 180 days post-surgery, with
earlier censoring for the end of insurance enrollment, subsequent mastectomy, implant, ﬂap, or nipple reconstruction.
We censored 1 day after the subsequent surgery because an SSI
coded within 1 day after surgery was considered preexisting
and attributable to the previous surgery. Non–breast-speciﬁc
SSI codes (eg, 998.59) were not classiﬁed as SSIs if they were
ﬁrst coded after a subsequent non-breast NHSN operation.
ICD-9-CM diagnosis codes for SSI or cellulitis coded from
30 days before to 1 day after mastectomy were considered
preexisting infections. For operations with a preexisting
infection, we required a minimum 30-day gap after mastectomy with no coding of SSI or cellulitis to identify an SSI
incident.
Indicators Consistent with Infection
Incision/drainage, implant removal or exchange, and outpatient
antibiotic prescription claims after mastectomy and within
14 days of a claim coded for SSI (before censoring) were
identiﬁed (Online Appendix 3). Antibiotic prescriptions within
2 days of mastectomy or mastectomy hospital discharge were
considered prophylactic and were excluded.
Statistical Analysis
The incidences of SSI within 180 days after mastectomy with
and without immediate reconstruction were compared using
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a χ2 test. A Kruskal-Wallis test was used for continuous
variables. All data management and statistical analyses were
performed using SAS v9.3 (SAS Institute, Cary, NC).

resul ts
A total of 19,422 mastectomy operations were initially identiﬁed from 2004 through 2011. The number of procedures was
reduced to 18,696 among 18,085 women after excluding procedures with no supporting evidence for operation (n = 208),
subsequent mastectomy operations following a bilateral mastectomy (n = 8), and dually coded operations that were more
likely BCSs (n = 510).
Immediate implant or ﬂap reconstruction was performed in
58% of operations (Tables 1 and 2). Women with reconstruction were younger, more likely to have bilateral mastectomy, and more likely to have the mastectomy performed
during an inpatient hospitalization. The majority of women
had local breast cancer, but a larger proportion of the
mastectomy-only population had regional or metastatic breast
cancer (27.3% vs 17.0%, P < .001). Women with prophylactic
mastectomy were more likely to have immediate reconstruction than women with other indications for mastectomy
[78.8% (565 of 717) vs 57.1% (10,271 of 17,979); P < .001].
The SSI incidence rate within 180 days following mastectomy with and without reconstruction was 8.1% (1,520 of
18,696). The SSI incidence rates were 5.0% after mastectomy
only, 10.3% after mastectomy plus implant, 10.7% after mastectomy plus ﬂap, and 10.3% after mastectomy plus ﬂap and
implant (P < .001; Table 2). Among mastectomies with and
without reconstruction, the SSI risk was signiﬁcantly higher
after bilateral compared with unilateral procedures (P = .001
and P = .021, respectively; Table 2). SSI incidence rates were
similar after prophylactic mastectomy with reconstruction
compared to mastectomy with reconstruction for other indications [10.1% (57 of 565) vs 10.4% (1,068 of 10,271);
P = .814]. The SSI incidence rate was higher for inpatient
versus outpatient procedures for mastectomy only [5.4% (301
of 5,523) vs 4.0% (94 of 2,337); P = .008], but the incidence
rates were similar for inpatient and outpatient procedures with
immediate reconstruction [10.4% (1,004 of 9,625) vs 10.0%
(121 of 1,211); P = .637].
The time to presentation with SSI varied depending on
whether mastectomy only or mastectomy plus immediate
reconstruction was performed (median time to onset 26 vs
33 days; P = .006). Among mastectomy-only patients, SSIs
were ﬁrst coded within 30 days post-mastectomy in 55.4%
(219 of 395) of procedures. Following mastectomy only, the
onset of 18% of SSIs were coded 31–60 days post-surgery, the
onset of 9.4% of SSIs were coded 61– 90 days post-surgery, and
the onset of 16.7% of SSIs were ﬁrst coded 91–180 days postsurgery (Figure 1). Among mastectomy patients with reconstruction, the onset of 47.2% of SSIs occurred within 30 days of
surgical procedures (531 of 1,125). Following mastectomy
with reconstruction, the onset of 27% of SSIs were coded
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table 1.

Characteristics of Mastectomy Operations in 18,085 Patients

Characteristic

Mastectomy only n (%)

Mastectomy with Immediate
Reconstruction n (%)

7,860
54 (18–64)
1,739 (22.1)

10,836
49 (18–64)
5,529 (51.0)

300 (3.8)
1,849 (23.5)
4,873 (62.0)
617 (7.9)
152 (1.9)
69 (0.9)
5,523 (70.3)

152 (1.4)
1,686 (15.6)
6,681 (61.7)
1,703 (15.7)
565 (5.2)
49 (0.5)
9,625 (88.8)

Total procedures
Age, median (range)
Bilateral mastectomy
Indication for mastectomy
Metastatic cancer
Regional cancer
Local breast cancer
Ductal carcinoma in situ
Prophylactic
Benign/other
Inpatient operation
a

august 2015, vol. 36, no. 8

P Valuea
<.001
<.001
<.001

<.001

P per χ test for categorical variables and Kruskal-Wallis test for continuous variables.
2

table 2. Incidence of Surgical Site Infection (SSI) For Mastectomy With and Without Immediate Reconstruction and
Unilateral versus Bilateral Operations
Operative Category

Total n (%)a

SSI within Surgery
Category n (%)

Relative Risk
(95% Conﬁdence Interval)

Mastectomy only
Mastectomy plus implant
Mastectomy plus ﬂap
Mastectomy plus ﬂap and implant

7,860 (42.0)
8,217 (44.0)
1,942 (10.4)
677 (3.6)

395 (5.0)
848 (10.3)
207 (10.7)
70 (10.3)

1.00
2.05 (1.83–2.30)
2.12 (1.81–2.49)
2.06 (1.62–2.62)

<.001

6,121 (32.7)
1,739 (9.3)
5,307 (28.4)
5,529 (29.6)

289 (4.7)
106 (6.1)
497 (9.4)
628 (11.4)

1.00
1.29 (1.04–1.60)
1.00
1.21 (1.08–1.36)

.021

P Valueb

Unilateral versus bilateral procedures
Unilateral mastectomy only
Bilateral mastectomy only
Unilateral mastectomy plus reconstruction
Bilateral mastectomy plus reconstruction
a

.001

Number and percentage of procedures compared to the total number of mastectomy procedures performed (N = 18,696).
P per χ2 test.

b

ﬁgure 1.

Days to surgical site infection (SSI) following mastectomy with and without immediate reconstruction (n = 1,520 SSI).

ssi post mastectomy and reconstruction

31–60 days post-surgery, the onset of 10.9% of SSIs were coded
61–90 days post-surgery, and the onset of 15.3% of SSIs were
ﬁrst coded 91–180 days post-surgery. The SSI incidence rates
within 30 days post-mastectomy with implant and with ﬂap
reconstruction were the same (47.3% and 46.4%, respectively).
Within 60 days post-mastectomy, the majority of the
infections characterized as SSIs (83.3%, 930 of 1,116) were
coded with a standard SSI code (eg, 683, 998.5x, or 996.69).
The remaining SSIs with onset ≤60 days post-mastectomy
were coded for cellulitis, staphylococcal infection, or breast
abscess plus incision and drainage or implant removal/
exchange (7.6%, n = 85) or breast abscess alone (9.1%,
n = 101). The SSI incidence rate with onset >60 days postmastectomy coded with standard SSI codes was lower than
that for SSIs with onset nearer the surgery date (62.9%, 254 of
404), and the incidence rates coded for cellulitis/staphylococcal infection with a wound care procedure (15.6%, n = 63)
and breast abscess alone (21.5%, n = 87) were higher than SSIs
with onset nearer the surgery date (P < .001).
Among women with prescription drug coverage (87% of
women with SSIs), SSI coding was present on a single claim for
36% (475 of 1,317). Of SSIs coded on only 1 claim, 86% (410
of 475) had additional evidence supporting the SSI diagnosis,
including 69% (n = 328) with an outpatient antibiotic prescription claim and 54% (n = 258) with an incision/drainage
or implant removal/exchange within 14 days of the SSI claim.

d i s c u s s io n
SSI incidence in this cohort of younger women was twice as high
after mastectomy with reconstruction compared with mastectomy
only and was higher after bilateral compared with unilateral procedures. The SSI incidence rate of 5.0% after mastectomy only is
consistent with infection rates reported in the last decade from
individual US institutions (Table 3).5,14,15 For mastectomy with
implant reconstruction, the SSI incidence rate was 10.3% compared with incidence rates in the surgical literature from individual US institutions since 2006, which range from 1.5% to 12.7%
(Table 3).5,16–24 The SSI incidence in our cohort for mastectomy
with ﬂap reconstruction was 10.7%. It is more difﬁcult to compare the SSI rate after immediate ﬂap reconstruction to rates
reported from individual institutions because the majority of
published studies do not separate infection rates after immediate
reconstruction versus delayed ﬂap reconstruction. SSI rates per
person reported after primarily immediate TRAM ﬂap reconstruction in the last decade range from 0.8% to 6.9%,5,22,25–28
although 3 of these studies did not speciﬁcally describe the
observation period for infection,22,25,27 and only our prior study
used the NHSN deﬁnition for SSI (Table 3).5
The NHSN breast surgery SSI rate is much lower than that
reported in our studies because the NHSN breast category
includes simpler procedures with lower SSI rates, such as
BCS,29 which can comprise a large proportion of breast
operations from some hospitals. The higher risk of SSI after
mastectomy compared with other breast procedures may be
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due in part to the larger incision, longer operative time, and
potential for large dead space after complete removal of the
breast with accumulation of lymphatic or serous ﬂuid. The
addition of reconstructive surgery, with or without a foreign
body and additional surgical site(s), increases the length of
procedure and further increases the risk of SSI.
In part, the variation in SSI rates reported after mastectomy
with immediate reconstruction in the surgical literature may
be due to variation in the deﬁnition used for infection
(Table 3). In a study of SSIs associated with implant reconstruction, implant removal was required to deﬁne infection,23
while in others intravenous antibiotic therapy22 and/or surgical treatment was required.18 In many reports, the criteria used
to deﬁne SSI were not stated.16,17,24,26–28 Most studies in the
surgical literature do not report infection rates per person but
rather per breast, making comparisons difﬁcult.
Recently, a number of investigators have used the American
College of Surgeons National Surgical Quality Improvement
Program (NSQIP) database to study 30-day complication rates
after breast operations. Nguyen et al reported an incidence of
SSI of 2.5% after mastectomy-only using 2005–2009 data,30
although partial and subcutaneous mastectomies were included, which have lower risk of SSI.5 Mioton et al reported an SSI
rate of 3.4% after mastectomy with immediate implant
reconstruction from 2006 to 2010,31 and Costa et al found that
the SSI rate after immediate ﬂap reconstruction was 4.9%
using 2005–2009 NSQIP data.32
In our present study, the 180-day incidence of SSI was 10.4%
after mastectomy with reconstruction compared with 5.0% after
mastectomy only, similar in magnitude to the difference in SSI
rates found previously in a single-institution study.5 When we
restricted the observation time to 30 days post-surgery, the SSI
incidence after mastectomy only in our current study was 2.8%,
very similar to the 2.5% rate reported by Nguyen et al using
NSQIP data. In contrast, the 30-day incidence of SSI we calculated after mastectomy with implant reconstruction was 4.9%,
higher than the 3.5% rate reported by Nguyen et al. In addition,
we found that only 47% of SSIs were coded within 30 days after
mastectomy with reconstruction. In a previous institutional
study, we found that 52% of SSIs were coded within 30 days after
mastectomy with implant reconstruction.6 This ﬁnding highlights the importance of continuing surveillance beyond 30 days
postoperatively to capture SSIs, particularly for operations
involving a foreign body, as recommended by NHSN.3
We found a signiﬁcantly higher incidence of SSI in women
with bilateral compared to unilateral mastectomy, both with
and without reconstruction. Osman et al reported higher risk
of SSIs after bilateral compared to unilateral mastectomy-only
in women with breast cancer using NSQIP data.33 In another
study using NSQIP data, Fischer et al found that bilateral
surgery was an independent risk factor for surgical complications.34 This is important information to present to women
given increasing use of contralateral prophylactic mastectomy
in women with unilateral breast cancer and bilateral prophylactic mastectomy in high-risk women.35,36
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Methods and Surgical Site Infection (SSI) Incidence Rates by Mastectomy and Type of Reconstruction

Reference
Mastectomy only
Olsen et al. (2008)5
Mortenson et al. (2004)14
Edwards et al. (2014)15
Mastectomy plus implanta
Olsen et al. (2008)5
Cordeiro & McCarthy (2006)16
Sbitany et al. (2009)17
Reish et al. (2013)18

Deﬁnition of SSI

No. Patients

12 mo
ND, mean 36 mo follow-up
Until postoperative evaluation

NHSN
ND
NHSN, or clinical diagnosis of cellulitis

12 mo
12 mo
ND
At least 1 yr

121
1,176
100
1,241

15 (12.4)
37 (3.1)
7 (7.0)
94 (7.6)

345

47 (8.6)b

378
203

48 (12.7)
23 (11.3)

334c
2,539
103

20 (6.0) cancer breast
18 (5.4) prophylactic breast
39 (1.5)
9 (8.7)

296
66
425

Weichman et al. (2013)19

ND

McCullough et al. (2014)20
Rundell et al. (2014)21

ND, median time to infection 29 d
ND, mean follow up 12 mo

Crosby et al. (2011)22

ND, mean follow up 13 mo

NHSN
ND
Infection requiring implant removal
Erythema suspicious for infection, treated with intravenous
antibiotics or implant removal
Infection requiring oral antibiotics (minor) or hospital
readmission and intravenous antibiotics (major)
NHSN
Infection requiring oral antibiotics (minor) or hospitalization,
intravenous antibiotics, or debridement (major)
Erythema plus intravenous antibiotics

Halvorson et al. (2007)24
Mitchell (2013)24
Mastectomy plus TRAM ﬂapd
Olsen et al. (2008)5
Crosby et al. (2011)22

At least 1 yr
At least 1 yr

Infection requiring implant removal
ND

12 mo
ND, mean follow up 13 mo

NHSN
Erythema plus intravenous antibiotics

Bristol et al. (2006)25
Meretoja et al. (2007)26
Chun et al. (2010)27

ND
5 yr
At least 11 mo, mean follow up 6 yr

Cellulitis or purulent discharge plus antibiotics
ND
ND

247
151
105

Kim et al. (2009)28

At least 1 yr, mean follow up 41 mo

ND

500

NOTE.
a

ND, not described; NHSN, National Healthcare Safety Network; TRAM, transverse rectus abdominis myocutaneous.
Sbitany (2009), unclear whether all implants were immediate reconstruction.
b
SSI and incidence is per breast (n = 546) rather than per person (n = 345).
c
All procedures were bilateral; SSI and incidence are per side (ie, cancer side and prophylactic side).
d
Bristol (2006) and Chun (2010), not all TRAMs were immediate reconstruction.
e
10 infections at the patient level; 6 breast SSIs; 7 donor site SSIs; 3 women had dual infections.

162
142c

SSI n (%)
13 (4.4)
3 (4.5)
31 (7.3)

10 (6.2)e
2 (1.4) cancer breast
3 ( 2.1) prophylactic breast
17 (6.9)
5 (3.3)
4 (3.8) breast
2 (1.9) donor site
4 (0.8) breast
5 (1.0) donor site
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table 3.

ssi post mastectomy and reconstruction

By deﬁnition, using claims data for SSI surveillance involves
secondary analysis of data collected for administrative purposes.
Potential exists for misclassiﬁcation of diagnoses and likely
undercoding of SSIs, particularly minor infections during the
90-day global surgical reimbursement period.37 Thus, our calculations for the incidence of SSI after mastectomy are likely
underestimates of the true infection rates after these procedures.
It is also possible that some SSIs classiﬁed as attributable to
mastectomy were due to another procedure, particularly infections coded >30 days after mastectomy in the absence of an
implant. We minimized this factor by censoring at the time of
subsequent breast and NHSN procedures, but it is possible that
an SSI could be attributable to a non-NHSN procedure. Finally,
we could not capture the onset of signs and/or symptoms of SSI
in claims data; we were limited to deﬁning the onset of infection
based on the ﬁrst paid claim coded for SSI, resulting in overestimation of the time to onset of infection in some cases.
The SSI incidence after mastectomy in this large, geographically diverse cohort of younger women was 8.1%, much
higher than the SSI incidence for breast surgical procedures
reported by the NHSN. Only half of all SSIs were coded on
medical claims within 30 days of surgery. Additional studies
with veriﬁcation of infection meeting NHSN deﬁnitions are
needed to determine whether longer-term SSI surveillance
after mastectomy is warranted. Our ﬁnding of variation in SSI
incidence for mastectomy only compared to mastectomy with
immediate reconstruction suggests that stratiﬁcation of SSI
rates by type of procedure is important.
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